论文部分内容阅读
目的观察单次大剂量重组人红细胞生成素治疗尿毒症维持性血液透析贫血患者的有效性和安全性。方法对30例维持性血液透析贫血患者,用重组人红细胞生成素10000U/次,每周1次,皮下注射,维持红细胞比容0.30～0.36,疗程8周。与常规剂量组(75U·kg~(-1)·次~(-1),每周2次)比较,观察血红蛋白和红细胞比容变化及不良反应的发生情况。结果30例尿毒症血液透析贫血患者治疗后血红蛋白和红细胞比容显著升高,总有效率100%,无不良反应,也无因难以控制的高血压而终止治疗者。长期治疗动、静脉内瘘闭塞发生率显著低于常规剂量组。结论单次大剂量重组人红细胞生成素皮下注射是治疗尿毒症贫血患者有效而安全的方法。
Objective To observe the efficacy and safety of a single high-dose recombinant human erythropoietin in patients with maintenance hemodialysis of uremia. Methods 30 patients with maintenance hemodialysis anemia, recombinant human erythropoietin 10000U / time, once a week, subcutaneous injection, maintaining hematocrit 0.30 ~ 0.36, treatment for 8 weeks. Compared with the conventional dose group (75U · kg -1, -1, twice a week), the change of hemoglobin and hematocrit and the incidence of adverse reactions were observed. Results The hemoglobin and hematocrit of 30 patients with hemodialysis hemodialysis were significantly increased after treatment, with a total effective rate of 100%, no adverse reactions and no termination of treatment due to uncontrolled hypertension. Long-term treatment of arterial and venous fistula occlusion was significantly lower than the conventional dose group. Conclusion A single high-dose recombinant human erythropoietin subcutaneously is an effective and safe treatment for uremic anemia patients.